Sutro Biopharma develops next-generation antibody-drug conjugates for oncology through a cell-free protein engineering platform. Recurring company news covers single- and dual-payload ADC design, pipeline programs such as STRO-004, STRO-006 and STRO-227, and preclinical data across tissue factor, ITGB6 and PTK7-targeting programs.
Updates also address clinical and regulatory disclosures, research and development collaborations, operating results, financing activity, equity compensation matters, investor and scientific conference participation, and Nasdaq listing compliance. The coverage reflects Sutro’s focus on site-specific ADCs for solid tumors and other cancer indications with limited treatment options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.